Duarte Machado, MD
Neurology · Cheshire, CTNPI 1649454976
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $331,969 of the $425,686 with a category attached, or 78.0%. 39 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 25.1% of the total. Reporting peaked in 2021 at $158,436 and has fallen 94.9% since, to $8,122 in 2025. Among neurology clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,059 payments — averaging $401.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$107K
- Adamas Pharmaceuticals, Inc.$72K
- Amneal Pharmaceuticals LLC$44K
- AbbVie$44K
- Kyowa Kirin, Inc.$33K
- MDD US Operations, LLC$31K
- plus $94K from 33 others
Across 38 payments — averaging $556.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- MDD US Operations, LLC$11K
- Neurocrine Biosciences, Inc.$9K
- Medtronic$1K
What the payments were for
- Consulting fees$54,08913%
- Speaking & faculty fees$331,96978%
- Travel & lodging$18,9454%
- Food & beverage$20,4665%
- Education$2170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INGREZZA$83,684
- GOCOVRI$75,466
- RYTARY$43,457
- Duopa$40,006
- NOURIANZ$33,210
- AUSTEDO$23,687
- XEOMIN$16,477
- PERCEPT PC BRAINSENSE$14,863
- ONGENTYS$14,426
- NORTHERA$12,691
- APOKYN$12,053
- MYOBLOC$10,591
- Xadago$7,553
- DYSPORT$6,765
- KYNMOBI$6,000
- NUPLAZID$4,025
- VERCISE$1,227
- ACTIVA PC$673
- Infinity DBS Pulse Generators$168
- ACTIVA$152
How this compares
$425,686 in reported general payments places this provider in the 95th percentile of 280 neurology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 44 | $609,793 |
| GocovriAmantadine Hcl | 183 | $565,288 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 27 | $511,670 |
| NuplazidPimavanserin Tartrate | 89 | $486,921 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 11 | $390,548 |
| RytaryCarbidopa/Levodopa | 279 | $376,831 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 23 | $368,391 |
| ApokynApomorphine Hcl | 14 | $345,893 |
| AustedoDeutetrabenazine | 33 | $272,531 |
| IngrezzaValbenazine Tosylate | 30 | $248,137 |
| NourianzIstradefylline | 108 | $242,250 |
| Austedo XrDeutetrabenazine | 24 | $128,829 |
| OngentysOpicapone | 107 | $92,623 |
| NeuproRotigotine | 53 | $68,749 |
| InbrijaLevodopa | 27 | $68,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Grifols USA, LLCGamunex-C | $42 | $609,79344 claims |
| MDD US Operations, LLCGocovri | $31,443 | $565,288183 claims |
| Acadia Pharmaceuticals IncNuplazid | $4,452 | $486,92189 claims |
| Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr | $24,711 | $401,36157 claims |
| Amneal Pharmaceuticals LLCRytary, Crexont | $44,492 | $385,762293 claims |
| Neurocrine Biosciences, Inc.Ingrezza, Ongentys | $106,767 | $340,760137 claims |
| Kyowa Kirin, Inc.Nourianz | $33,432 | $242,250108 claims |
| AbbVieLinzess, Ubrelvy, Qulipta | $43,728 | $91,43699 claims |
| UCB, Inc.Neupro | $129 | $68,74953 claims |
| Acorda Therapeutics, IncInbrija | $169 | $68,35427 claims |
| PfizerNurtec Odt | $586 | $45,39731 claims |
| Arbor Pharmaceuticals, Inc.Horizant | $233 | $41,12229 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 280 neurology providers in Connecticut.
Other neurology in Cheshire
- Michelle DagostineCheshire$239K
- Peter McAllisterFairfield$2.3M
- Stewart TepperStamford$1.2M
- Sharon StollNew Haven$822K
- Mary BaileyNew Haven$630K
- Wanda Castro-BorreroFarmington$553K
- Derek SmithNorwich$469K
- Deena KuruvillaWestport$440K
- Tanya BilchikEast Hartford$361K
- Peter GottschalkFairfield$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.